LAURUSLABS Stock Overview
Manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Laurus Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹429.30 |
| 52 Week High | ₹484.30 |
| 52 Week Low | ₹349.40 |
| Beta | 1.17 |
| 11 Month Change | -10.03% |
| 3 Month Change | -0.035% |
| 1 Year Change | 7.28% |
| 33 Year Change | -38.94% |
| 5 Year Change | 527.63% |
| Change since IPO | 346.82% |
Recent News & Updates
Here's Why It's Unlikely That Laurus Labs Limited's (NSE:LAURUSLABS) CEO Will See A Pay Rise This Year
Jul 05
Laurus Labs Limited's (NSE:LAURUSLABS) Price In Tune With Revenues
Jul 03Recent updates
Here's Why It's Unlikely That Laurus Labs Limited's (NSE:LAURUSLABS) CEO Will See A Pay Rise This Year
Jul 05Laurus Labs Limited's (NSE:LAURUSLABS) Price In Tune With Revenues
Jul 03Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.40
Apr 28Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jan 27Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?
Dec 01Laurus Labs (NSE:LAURUSLABS) Is Paying Out Less In Dividends Than Last Year
Oct 22These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Reasonably Well
Jul 06Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Dividend Of ₹1.20
Apr 30Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?
Dec 18Is Laurus Labs Limited (NSE:LAURUSLABS) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 27Is Laurus Labs (NSE:LAURUSLABS) Using Too Much Debt?
Sep 09Laurus Labs (NSE:LAURUSLABS) Has A Somewhat Strained Balance Sheet
Jun 11Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Larger Dividend Than Last Year
May 02Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Feb 26With EPS Growth And More, Laurus Labs (NSE:LAURUSLABS) Is Interesting
Feb 11Does Laurus Labs (NSE:LAURUSLABS) Have A Healthy Balance Sheet?
Nov 26Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.80
Nov 13I Ran A Stock Scan For Earnings Growth And Laurus Labs (NSE:LAURUSLABS) Passed With Ease
Nov 12Laurus Labs (NSE:LAURUSLABS) Has Affirmed Its Dividend Of ₹0.80
Oct 30A Look At The Intrinsic Value Of Laurus Labs Limited (NSE:LAURUSLABS)
Oct 05Should You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?
Aug 10Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Jul 23Is Laurus Labs Limited (NSE:LAURUSLABS) Worth ₹547 Based On Its Intrinsic Value?
Jun 06We Think That There Are Issues Underlying Laurus Labs' (NSE:LAURUSLABS) Earnings
May 06Should You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?
May 05We Think Laurus Labs (NSE:LAURUSLABS) Can Stay On Top Of Its Debt
Mar 16Shareholder Returns
| LAURUSLABS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -4.8% | 2.1% | -0.02% |
| 1Y | 7.3% | 48.8% | 45.4% |
Return vs Industry: LAURUSLABS underperformed the Indian Pharmaceuticals industry which returned 48.8% over the past year.
Return vs Market: LAURUSLABS underperformed the Indian Market which returned 45.4% over the past year.
Price Volatility
| LAURUSLABS volatility | |
|---|---|
| LAURUSLABS Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: LAURUSLABS has not had significant price volatility in the past 3 months.
Volatility Over Time: LAURUSLABS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 6,007 | Satyanarayana Chava | www.lauruslabs.com |
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs.
Laurus Labs Limited Fundamentals Summary
| LAURUSLABS fundamental statistics | |
|---|---|
| Market cap | ₹231.46b |
| Earnings (TTM) | ₹1.48b |
| Revenue (TTM) | ₹50.54b |
156.2x
P/E Ratio4.6x
P/S RatioIs LAURUSLABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAURUSLABS income statement (TTM) | |
|---|---|
| Revenue | ₹50.54b |
| Cost of Revenue | ₹24.93b |
| Gross Profit | ₹25.61b |
| Other Expenses | ₹24.13b |
| Earnings | ₹1.48b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.75 |
| Gross Margin | 50.68% |
| Net Profit Margin | 2.93% |
| Debt/Equity Ratio | 62.6% |
How did LAURUSLABS perform over the long term?
See historical performance and comparison